Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AVTX | US
0.11
1.07%
Healthcare
Biotechnology
30/06/2024
17/10/2024
10.40
10.18
10.43
9.65
Avalo Therapeutics Inc. a clinical stage biotechnology company focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002 a fully human anti-LIGHT monoclonal antibody which is under Phase II clinical trial for the treatment of non-eosinophilic asthma as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008 a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803 a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics Inc. in August 2021. Avalo Therapeutics Inc. was incorporated in 2011 and is headquartered in Rockville Maryland.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
92.4%1 month
88.5%3 months
98.8%6 months
96.4%-
-
1.66
-0.80
0.02
-0.19
2.74
-
-22.05M
100.88M
100.88M
-
-2.75K
-
-36.30
-524.01
3.46
0.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.43
Range1M
1.94
Range3M
6.16
Rel. volume
0.25
Price X volume
38.02K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Adagene Inc. | ADAG | Biotechnology | 2.41 | 108.71M | 0.84% | n/a | 36.49% |
Bright Minds Biosciences Inc. Common Stock | DRUG | Biotechnology | 21.7 | 107.00M | -24.65% | n/a | 0.23% |
Genenta Science S.p.A | GNTA | Biotechnology | 5.76 | 104.93M | -1.54% | n/a | 0.00% |
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.92 | 104.84M | -1.03% | n/a | 9.99% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 3.46 | 102.04M | -6.49% | n/a | 81.33% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.52 | 99.51M | -4.40% | n/a | 1.45% |
INmune Bio Inc | INMB | Biotechnology | 5 | 99.16M | -4.03% | n/a | 14.65% |
Agenus Inc | AGEN | Biotechnology | 4.57 | 98.58M | -2.35% | n/a | -170.56% |
Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.28 | 98.38M | 2.40% | n/a | 0.00% |
Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 2.4 | 97.85M | -1.23% | 4.67 | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.05 | 92.04M | -1.35% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.35 | 89.85M | 0.07% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.19 | 0.53 | Cheaper |
Ent. to Revenue | 2.74 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.66 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 98.82 | 72.92 | Riskier |
Debt to Equity | -0.80 | -1.24 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 100.88M | 3.78B | Emerging |